<DOC>
	<DOCNO>NCT01903694</DOCNO>
	<brief_summary>Principal objective : evaluate effect combination pravastatin - sorafenib versus sorafenib alone overall survival patient hepatocellular carcinoma develop Child-Pugh A cirrhosis unsuitable curative treatment . Secondary objective : evaluate effect treatment progression-free survival , time progression , time treatment failure quality life ( QLQ-C30 et FACT HEP )</brief_summary>
	<brief_title>Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone Palliative Treatment Child-Pugh A Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Hepatocellular carcinoma diagnose : either histological examination histological evidence obtain ( ascites , coagulation disorder ) diagnosis make case cirrhosis accord EASL/AASLD 2005 criterion , reveal hepatic focal lesion 10 mm two dynamic image technique ( helical CTscan , MRI , contrastenhanced ultrasound ) tumours measure less 2 cm . The lesion must characterise hyperdensity arterial phase washout delayed portal phase Patients suitable treatment curative intent ( transplantation , resection , percutaneous destruction ) chemoembolisation progressive hepatocellular carcinoma failure specific treatment Prognostic CLIP score 0 4 ChildPugh Class A Transaminases ≤ 5 N Creatininemia ≤ 1.5 N WHO : 0 , 1 2 Age 18 year Foreseeable survival &gt; 12 week Possibility regular followup Written inform consent Extrahepatic disease could lifethreatening short medium term Another progressive cancer exception situ cervical cancer , superficial bladder tumour treat basocellular carcinoma . Any cancer treat curative intent previous 3 year include study Heart failure ( ≥New York Heart Association class 2 ) , uncontrolled AHT arrhythmia , myocardial infarction previous 6 month Digestive haemorrhage previous month Patients receive already receive treatment statin sorafenib Pregnancy breastfeeding . Women childbearing age must use effective method contraception throughout trial 3 month end treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>